| Literature DB >> 33061240 |
Alshimaa A Hassanien1, Eman M Shaker2.
Abstract
BACKGROUND AND AIM: Antimicrobial-resistant Escherichia coli O157:H7 causes serious diseases in humans, especially when circulated in their food. This study was designed to detect the presence of E. coli O157:H7 using the fliC H7 gene in some milk products as kareish cheese, labena, and yoghurt sold in Sohag city, Egypt, and among diarrheal patients admitted to governmental hospitals in Sohag and also to highlight the risk factors associated with their infection. In addition, the antimicrobial resistance and the effect of chitosan nanoparticles (CNP) and silver nanoparticles (SNP) on E. coli O157:H7 isolates obtained from both milk products and patients were investigated.Entities:
Keywords: Escherichia coli O157:H7; chitosan nanoparticles; diarrheal patients; kariesh cheese; labena; silver nanoparticles
Year: 2020 PMID: 33061240 PMCID: PMC7522957 DOI: 10.14202/vetworld.2020.1647-1653
Source DB: PubMed Journal: Vet World ISSN: 0972-8988
Frequency distribution of E. coli O157:H7 in milk products and patients.
| Positive samples | Milk products | Diarrheal patients n=150 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kariesh cheese n=50 | Labena n=50 | Yoghurt n=50 | Total n=150 | |||||||
| n | % | n | % | n | % | n | % | n | % | |
| 12 | 24 | 3 | 6 | 2 | 4 | 17 | 11.3 | 22 | 14.7 | |
n=Number of samples, E. coli=Escherichia coli
Figure-1PCR result for E. coli O157:H7 detection. Lane M: 100 bp ladder (Norgen Bioteck), Lane 1: Negative, Lane: 2,3,4,5, 6 and 7: Positive.
Patient characteristics and factors related to infection with E. coli O157:H7.
| Risk factors | Diarrheal patients n=150 | Patients with | p-value | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age[ | 0.815 | ||||
| <6 | 35 | 23.3 | 6 | 27.3 | |
| 6-15 | 17 | 11.3 | 3 | 13.6 | |
| 16-25 | 14 | 9.3 | 1 | 4.5 | |
| 26-35 | 12 | 8 | 2 | 9.1 | |
| 36-45 | 19 | 12.7 | 2 | 9.1 | |
| 46-55 | 25 | 16.7 | 3 | 13.6 | |
| >55 | 28 | 18.7 | 5 | 22.7 | |
| Gender[ | 0.936 | ||||
| Female | 67 | 44.7 | 10 | 45.5 | |
| Male | 83 | 55.3 | 12 | 54.5 | |
| Exposure to infection | |||||
| Contact with infected persons[ | 97 | 64.7 | 9 | 40.9 | 0.05 |
| Contact with animals | 14 | 9.3 | 3 | 13.6 | 0.456 |
| Medical history | 86 | 57.3 | 18 | 81.8 | 0.05 |
| Liver diseases | 24 | 16 | 3 | 13.6 | |
| Renal diseases | 31 | 20.7 | 12 | 54.5 | |
| Heart diseases | 16 | 10.7 | 5 | 22.7 | |
| Bronchial asthma | 39 | 26 | 1 | 4.5 | |
| DM | 71 | 47.3 | 9 | 40.9 | |
| Hypertension | 63 | 42 | 6 | 27.3 | |
| Pregnancy | 16 | 33.3 | 1 | 4.5 | |
Significant factors,
Non-significant factors,
Some patients suffer from more than one disease, n=Number of samples. E. coli=Escherichia coli, DM=Diabetes Mellitus
Antimicrobial profile of E. coli O157:H7 isolated from milk products and diarrheal patients.
| Antimicrobial | Milk products isolates n=17 | Diarrheal patients isolates n=22 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Penicillins | ||||||||||||
| AMP 10 µg | 0 | 0 | 1 | 5.9 | 16 | 94.1 | 1 | 4.5 | 2 | 9.1 | 19 | 86.4 |
| β-Lactamase | ||||||||||||
| AMC 30 µg | 7 | 41.2 | 2 | 11.8 | 8 | 47.1 | 6 | 27.3 | 2 | 9.1 | 14 | 63.6 |
| Cephalosporins | ||||||||||||
| CRO 30 µg | 5 | 29.4 | 4 | 23.5 | 8 | 47.1 | 4 | 18.2 | 6 | 27.3 | 12 | 54.5 |
| FOX 30 µg | 11 | 64.7 | 4 | 23.5 | 2 | 11.8 | 16 | 72.7 | 4 | 18.2 | 2 | 9.1 |
| Aminoglycosides | ||||||||||||
| CN 10 µg | 0 | 0 | 3 | 17.6 | 14 | 82.3 | 3 | 13.6 | 3 | 13.6 | 16 | 72.7 |
| AK 30 µg | 9 | 52.9 | 1 | 5.9 | 7 | 41.2 | 10 | 45.5 | 5 | 22.7 | 7 | 31.8 |
| Tetracyclines | ||||||||||||
| TE 30 µg | 2 | 11.8 | 0 | 0 | 15 | 88.2 | 1 | 4.5 | 3 | 13.6 | 18 | 81.8 |
| Quinolones | ||||||||||||
| CIP 5 µg | 7 | 41.2 | 5 | 29.4 | 5 | 29.4 | 10 | 45.5 | 6 | 27.3 | 6 | 27.3 |
| OFX 5 µg | 15 | 88.2 | 2 | 11.8 | 0 | 0 | 17 | 77.3 | 2 | 9.1 | 3 | 13.6 |
| Phenicols | ||||||||||||
| C 30 µg | 1 | 5.9 | 5 | 29.4 | 11 | 64.7 | 10 | 45.5 | 4 | 18.2 | 8 | 36.4 |
AMP=Ampicillin, AMC=Amoxicillin/clavulanic acid, CRO=Ceftriaxone, FOX=Cefoxitin, CN=Gentamycin, AK=Amikacin, TE=Tetracycline, CIP=Ciprofloxacin, OFX=Ofloxacin, C=Chloramphenicol, n=Number of isolates
Inhibitory effect of CNP and SNP on E. coli O157:H7 isolates from milk products and diarrheal patients.
| Concentration (µg/mL) | Inhibition zone (mm) | ||||||
|---|---|---|---|---|---|---|---|
| Milk product isolates | |||||||
| CNP | SNP | p-value | |||||
| Min. | Max. | Mean±SE | Min. | Max. | Mean±SE | ||
| 30 | 15 | 22 | 19.705±2.201 | 19 | 28 | 23.294±3.704 | 0.05 |
| 60 | 24 | 35 | 31.941±3.749 | 31 | 40 | 33.588±3.675 | |
| 30 | 16 | 22 | 18.363±2.341 | 17 | 27 | 19.727±3.042 | 0.05 |
| 60 | 25 | 36 | 30.681±3.871 | 30 | 39 | 32.500±2.444 | |
CNP=Chitosan nanoparticles, SNP=Silver nanoparticles, E. coli=Escherichia coli, SE: Standard error
Figure-2(a) CNP with average size 25.1 nm. (b) SNP with average size 26.5 nm.